Rain Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Rain Oncology

03/03/2022 22:39

* Rain Therapeutics Inc  RAIN.OQ  reported a quarterly
adjusted
loss of 68 cents​​ per share for the quarter ended in December.
The mean expectation of four analysts for the quarter was for a
loss of 56 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * Rain Therapeutics Inc's reported EPS for the quarter was a
loss
of 68 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Rain Therapeutics Inc shares had fallen by 54.4% this
quarter.
    * The company reported a quarterly loss of $17.99 million.
    * Wall Street's median 12-month price target for Rain
Therapeutics
Inc is $23.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated March 3 at 10:38 p.m.  ​All
figures in US dollars unless otherwise stated